Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Differentiating therapy in acute myeloid leukemia

M S Tallman1

  • 1Northwestern University Medical School, Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL, USA.

Leukemia
|June 1, 1996
PubMed
Summary

All-trans retinoic acid (ATRA) effectively treats acute promyelocytic leukemia (APL) by inducing differentiation, leading to complete remission and resolving coagulopathy. Ongoing research compares ATRA to chemotherapy to further define its role in APL treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.

Bone marrow transplantation·2024
Same author

Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.

Bone marrow transplantation·2024
Same author

Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes.

Leukemia research·2020
Same author

The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.

Bone marrow transplantation·2017
Same author

Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia.

Leukemia·2017
Same author

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Leukemia·2017

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Differentiating therapy, using agents like all-trans retinoic acid (ATRA), is a novel antineoplastic strategy.
  • ATRA has shown remarkable activity in treating acute promyelocytic leukemia (APL).
  • Early studies demonstrated ATRA's ability to induce leukemic cell differentiation in vitro.

Purpose of the Study:

  • To evaluate the clinical activity and benefit of ATRA in patients with APL.
  • To assess the efficacy of ATRA in achieving complete remission (CR) and resolving coagulopathy.
  • To investigate the comparative benefits of ATRA versus conventional chemotherapy in APL treatment.

Main Methods:

  • Clinical trials involving newly diagnosed and previously treated APL patients.
  • Prospective randomized trials comparing ATRA plus chemotherapy to chemotherapy alone.
  • Ongoing large intergroup trials comparing conventional chemotherapy with ATRA for induction and maintenance.

Main Results:

  • ATRA induces CR in the majority of APL patients, including those previously treated with chemotherapy.
  • Characteristic life-threatening coagulopathy associated with APL resolves rapidly with ATRA treatment.
  • Early trials indicate improved event-free survival with ATRA due to a reduced relapse rate.

Conclusions:

  • ATRA is a highly effective treatment for APL, inducing CR and resolving coagulopathy.
  • Limitations such as retinoid resistance and the retinoic acid syndrome require careful management.
  • ATRA represents a paradigm for targeted differentiating therapy in hematologic malignancies.

Related Experiment Videos